FDA approves Sandoz’s natalizumab biosimilar, likely putting a damper on Biogen’s Tysabri sales

On the back of San­doz’s FDA ap­proval for the first-ever na­tal­izum­ab biosim­i­lar, brand­ed as Tyruko, Bio­gen now has a for­mi­da­ble mul­ti­ple scle­ro­sis mar­ket com­peti­tor for its top-sell­ing mon­o­clon­al an­ti­body Tysabri.

“Tyruko has the po­ten­tial to ex­tend the reach of na­tal­izum­ab treat­ment for these pa­tients, in­crease health­care sav­ings and fu­el in­no­va­tion through com­pe­ti­tion in the mar­ket,” San­doz North Amer­i­ca pres­i­dent Keren Haru­vi said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.